Biotech News
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
ir.crisprtx.com2026-05-06 14:45 EST
-Positive Phase 1 data for CTX310 ® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine - -CASGEVY ® momentum accelerating; nearly 300 patients have been referred to Authorized